Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 16/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.33 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20158631 | 0.87 | RET (0.43) | RETEGLN1 | |
| SCHEMBL25502427 | 0.84 | RET (0.50) | RETCYP3A4CYP2D6SLC5A7EGLN1 | |
| SCHEMBL25502428 | 0.82 | RET (0.51) | RETCYP3A4CYP2D6SLC5A7 | |
| SCHEMBL20069619 | 0.76 | RET (0.52) | RETEGLN1 | |
| SCHEMBL20069627 | 0.76 | RET (0.52) | RETCYP2D6 | |
| SCHEMBL22856985 | 0.73 | RET (0.52) | RETEGLN1 | |
| SCHEMBL20137436 | 0.72 | RET (0.51) | RETCYP3A4CYP2D6 | |
| SCHEMBL20137435 | 0.72 | RET (0.51) | RETCYP3A4CYP2D6 | |
| SCHEMBL20147950 | 0.72 | RET (0.50) | RETCYP2D6 | |
| SCHEMBL20148104 | 0.71 | RET (0.48) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885CYP3A4 3760/4885CYP2D6 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.